|  |  |  |  |
| --- | --- | --- | --- |
|  | **OR**  **(n = 68)** | **Office**  **(n = 37)** | **P-value** |
| 6-month treatment outcome  Treatment failure  Retreatment | 23 (33.8%)  16 (23.5%) | 13 (35.1%)  9 (24.3%) | p > 0.999  p > 0.999 |
| 12-month treatment outcome  Treatment failure  Retreatment | 17 (50.0%)  10 (29.4%) | 9 (37.5%)  7 (28.0%) | p = 0.426  p > 0.999 |
| Post-procedure urinary retentiona | 11 (16.4%) | 1 (2.7%) | p = 0.052 |
| Post-procedure UTI  UTI treatment  Culture-proven | 12 (17.9%)  7 (10.5%) | 5 (13.5%)  3 (8.1%) | p = 0.783  p > 0.999 |
| Retreatment for SUI  Urethral bulking  Pelvic floor physical therapy  Pessary  Midurethral sling | 12 (19.1%)  1 (1.5%)  1 (1.5%)  7 (10.3%) | 3 (8.1%)  4 (10.8%)  0 (0%)  3 (8.1%) | p = 0.164  p = 0.051  p > 0.999  p > 0.999 |
| Anesthesia during procedure  Local  Sedation  General | 2 (2.9%)  58 (85.3%)  8 (11.8%) | 37 (100%)  0 (0%)  0 (0%) | **p < 0.001** |
| Antibiotic prophylaxis during procedure  Cefoxitin  Cefazolin  Nitrofurantoin  Other  None | 54 (80.6%)  10 (14.9%)  0 (0%)  1 (1.5%)  2 (3.0%) | 0 (0%)  0 (0%)  7 (18.9%)  4 (10.8%)  26 (70.3%) | **p < 0.001** |
| Phenazopyridine during procedure | 4 (5.9%) | 5 (13.5%) | p = 0.27 |
| PAH injection volume, mL | 2 (2 – 2) | 2 (1.6 – 2) | **p < 0.05** |
| Cough stress test performed during procedure | 8 (11.8%) | 19 (57.6%) | **p < 0.001** |
| Procedure aborted | 0 (0%) | 4 (10.8%) | **p < 0.05** |
| Concurrent procedures  Intravesical onabotulinum toxin A  Pelvic floor muscle injections  Pelvic organ prolapse surgery  Other surgeryb | 14 (20.6%)  3 (4.4%)  4 (5.9%)  7 (10.3%) | 6 (16.2%)  0 (0%)  0 (0%)  0 (0%) | p = 0.80  p = 0.55  p = 0.30  p = 0.05 |
| Surgeon  Surgeon A  Surgeon B  Surgeon C  Surgeon D  Surgeon E  Surgeon F  Surgeon G  Surgeon H  Surgeon I | 9 (13.2%)  7 (10.3%)  0 (0%)  6 (8.8%)  20 (29.1%)  5 (7.4%)  2 (2.94%)  12 (17.7%)  7 (10.3%) | 3 (8.1%)  5 (13.5%)  3 (8.1%)  3 (8.1%)  11 (29.7%)  10 (27.0%)  1 (2.7%)  0 (0%)  1 (2.7%) | **p < 0.01** |

a As documented by history.

b Includes hysterectomy for non-prolapse indication, excision of endometriotic implants, hymenectomy, mesh excision, and bladder instillations.

PAH, polyacrylamide hydrogel; SUI, stress urinary incontinence; UTI, urinary tract infection